IDS and mucopolysaccharidosis type 2: Despite these limitations, the results from this analysis provide keyinsights into the impact of idursulfase treatment on clinical manifestations of MPSII during the first 3 years of treatment, and complement and extend the findingsfrom the formal clinical trials and other smaller-scale studies of idursulfasetreatment.